 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Alkermes plc. (ALKS) researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. 
Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases.
The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells.
Shares have formed a bullish "cup and handle" following the company's latest quarterly report. On April 27th, it reported 1st Quarter March 2022 earnings of $0.01 per share on revenue of $278.5 million. The consensus estimate was a loss of $0.14 per share on revenue of $252.6 million. Revenue grew 10.8% on a year-over-year basis.
The company said it continues to expect 2022 non-GAAP non-GAAP results to range from a loss of $0.18 per share to breakeven on revenue of $1.00 billion to $1.09 billion. The previous consensus estimate was a loss of $0.10 per share on revenue of $1.04 billion for the year ending December 31, 2022. Higher share prices are expected.
Entry Point: $28.85
Trading Range: $21.17 to $33.00
Stop Loss: $27.00
Target Price: $31.80
ALKS closed at $29.5
